Article info

Download PDFPDF

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Authors

  • Marijo Bilusic Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Christopher R. Heery Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA Precision Biosciences Durham NC USA PubMed articlesGoogle scholar articles
  • Julie M. Collins Medical Oncology Service, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Renee N. Donahue Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Claudia Palena Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Ravi A. Madan Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Fatima Karzai Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Jennifer L. Marté Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Julius Strauss Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Margaret E. Gatti-Mays Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Jeffrey Schlom Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • James L. Gulley Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer InstituteNational Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  1. a marijo.bilusic{at}nih.gov
  2. b Christopher.Heery{at}bavarian-nordic.com
  3. c julie.collins{at}nih.gov
  4. d renee.donahue{at}nih.gov
  5. e palenac{at}mail.nih.gov
  6. f madanr{at}mail.nih.gov
  7. g fatima.karzai{at}nih.gov
  8. h jenn.marte{at}nih.gov
  9. i julius.strauss{at}nih.gov
  10. j margaret.gatti-mays{at}nih.gov
  11. k schlomj{at}mail.nih.gov
  12. l gulleyj{at}mail.nih.gov
View Full Text

Citation

Bilusic M, Heery CR, Collins JM, et al
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Publication history

  • Received April 9, 2019
  • Accepted August 7, 2019
  • First published September 5, 2019.
Online issue publication 
September 05, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.